Ursodeoxycholic acid for primary biliary cirrhosis

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Gong, Yan ^a   Zhi, Bi Huang ^b   Christensen, Erik ^c   Gluud, Christian ^d  

^a University of Copenhagen ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d Mental Health Services CPH   (Denmark)

Author keywords

*Therapeutic use ; Administration, oral; Cholagogues and choleretics adverse effects; Humans; Liver cirrhosis, biliary *drug therapy ; Randomized controlled trials as topic; Ursodeoxycholic acid adverse effects

Indexed keywords

BILIRUBIN; COLCHICINE; PLACEBO; PREDNISOLONE; URSODEOXYCHOLIC ACID;

BAYES THEOREM; BEDTIME DOSAGE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FATIGUE; HEALTH CARE COST; HUMAN; JAUNDICE; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MORTALITY; NAUSEA; PORTAL VEIN BLOOD PRESSURE; PRIMARY BILIARY CIRRHOSIS; PRURITUS; REVIEW; RISK; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

EID: 55049110775     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000551.pub2     Document Type: Review

References (195)

1. ATHENS {published data only} Hadziyannis S, Hadziyannis E. A randomised controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) (AASLD Abstract). Hepatology 1988;8:1421.
2. Hadziyannis SJ. Long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid: the third year of a controlled trial. XI International Bile Acid Meeting. Bile Acids as Therapeutic Agents - From Basic Science to Clinical Practice. Freiburg. 1990:57-8.
3. Hadziyannis SJ, Hadziyannis ES, Lianidou E, Makris A. Long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid: the third year of a controlled trial. Bile Acids as Therapeutic Agents. From Basic Science to Clinical Practice. Falk Symposium 58. 1990: 287-96.
4. Hadziyannis SJ, Hadziyannis ES, Makris A. A randomized controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) [abstract]. Hepatology 1989;10:580.
5. Papatheodoridis GV, Deutsch M, Hadziyannis E, Tzakou A, Hadziyannis SJ. Ursodeoxycholic-acid for primary biliary cirrhosis: final results of a 12-year prospective, randomised, controlled trial. Journal of Hepatology 2000;32(Suppl 2):40.
6. * Papatheodoridis GV, Hadziyannis ES, Deutsch M, Hadziyannis SJ. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. The American Journal of Gastroenterology 2002;97:2063-70.
7. BARCELONA {published and unpublished data} Pares A, Caballeria L, Bruguera M, Rodes J. Factors influencing histological progression of early primary biliary cirrhosis. Effect of ursodeoxycholic acid. J Hepatol 2001;34(Suppl 1):189-90.
8. Pares A, Caballeria L, Rodes J. Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis. Journal of Hepatology 2001;34(Suppl 1):187-8.
9. * Parés A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, et al.Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. Journal of Hepatology 2000;32:561-6.
10. Parés A for the Spanish Association for the Study of the Liver. Long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid: results of a randomized, double-blind, placebo-controlled trial (abstract). J Hepatol 1997;26(Suppl 1):166.
11. DALLAS {published data only} Carithers RL, Luketic VA, Peters M, Zetterman RK, Garcia-Tsao G, et al.Extended follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis (Abstract). Gastroenterology 1996;110(4):A1163.
12. Combes B, Carithers RL, Maddrey WC, Munoz SJ, McDonald MF, Garcia-Tsao G, et al.A randomized, double-blind, placebo-controlled trial of ursodeoxcholic acid (UDCA) in primary biliary cirrhosis (AASLD Abstract). Hepatology 1993;18:175A.
13. Combes B, Carithers RL, Maddrey WC, Munoz SJ, McDonald MF, Garcia-Tsao G, et al.A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC). Falk Symposium No. 68. XII International Bile Acid Meeting. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Basel. 1992:43.
14. Combes B, Carithers RL, Maddrey WC, Munoz SJ, McDonald MF, Garcia-Tsao G, et al.A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Falk Symposium 68. 1993:289-91.
15. Combes B, Carithers RL, Maddrey WC, Munoz SJ, McDonald MF, Garcia-Tsao G, et al.The American multicenter primary biliary cirrhosis, Ursodiol versus placebo study group (PUPS) trial. Falk Symposium No. 80. XIII International Bile Acid Meeting. Bile Acids in Gastroenterology: Basic and Clinical Aspects. San Diego. 1994:67.
16. * Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al.A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-66.
17. Combes B, Carithers RL Jr, McDonald MF, Maddrey WC, Munoz SJ, Boyer JL, et al.Ursodeoxycholic acid therapy in patients with primary biliary cirrhosis [AASLD abstract]. Hepatology 1991;14:91A.
18. Combes B, Markin RS, Wheeler DE, Rubin R, West AB, Mills AS, et al.The effect of ursodeoxycholic acid on the florid duct lesion of primary biliary cirrhosis. Hepatology 1999;30:602-5.
19. Emond M, Carithers RL Jr, Luketic VA, Peters M, Zetterman RK, Garcia-Tsao G, et al.Does ursodeoxycholic acid improve survival in patients with primary biliary cirrhosis? Comparison of outcome in the US multicenter trial to expected survival using the Mayo Clinic prognostic model [AASLD abstract]. Hepatology 1996;24:168A.
20. FRANKFURT {published and unpublished data} Güldütuna S, Leuschner U, Imhof M, Zimmer G. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid. Z-Gastroenterol 1992;30 Suppl 1:49-54.
21. Leuschner M, Güldütuna S, Imhof M, Bhati S, You T, Leuschner U. Ursodeoxycholic acid therapy in primary biliary cirrhosis. Bile acids and the hepatobiliary system. From Basic Science to Clinical Practice. Falk Symposium 68. 1993:299-302.
22. Leuschner U, Fischer H, Güldütuna S, Kurtz W, Gatzen M, Hellstern A, et al.Does ursodeoxycholic acid (UDCA) influence cell membrane architecture in patients with primary biliary cirrhosis (PBC)?. Gastroenterology 1989;96:A621.
23. Leuschner U, Fischer H, Hübner K. UDCA in der Behandlung der primären biliären Zirrhose: Ergebnisse einer kontrollierten Studie. Ergebnisse der Gastroenterologie 1989;24:133.
24. * Leuschner U, Fischer H, Kurtz W, Güldütuna S, Hubner K, Hellstern A, et al.Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989;97:1268- 74.
25. Leuschner U, Fisher H, Hübner K, Güldütuna S, Gatzen M, Hellstern A, et al.Ursodeoxycholic acid (UDCA) treatment of primary biliary cirrhosis: clinical and histological results of a controlled study. Trends in Bile Acid Research. Falk Symposium 52. 1989:355-8.
26. GÖTEBORG {published and unpublished data} * Eriksson LS, Olsson R, Glauman H, Prytz H, Befrits R, Ryden BO, et al.Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study. Scand-J-Gastroenterol 1997;32:179-86.
27. HELSINKI {published and unpublished data} Kisand KE, Karvonen A-L, Vuoristo M, Färkkilä M, Lehtola J, Inkovaara J, et al.Ursodeoxycholic acid treatment lowers the serum levels of antibodies against pyrovate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis. Journal of Molecular Medicine 1996;74:269-74.
28. Miettinen TA, Farkkila M, Vuoristo M, Karvonen AL, Leino R, Lehtola J, et al.Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine. Hepatology 1995;21:1261-8.
29. Miettinen TA, Färkkila M, Vuoristo M, Karvonen A-L, Leino R, Lehtola J, et al.Improvement of serum noncholesterol sterols may indicate retarded progression of primary biliary cirrhosis (PBC) in a randomized placebo controlled two-year trial with colchicine and ursodeoxycholic acid (AASLD abstract). Gastroenterology 1993;104:A954.
30. Vuoristo M, Färkkilä M, Gylling H, Karvonen A-L, Leino R, Lehtola J, et al.Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis. Journal of Hepatology 1997;27:136-42.
31. * Vuoristo M, Farkkila M, Karvonen AL, Leino R, Lehtola J, Makinen J, et al.A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid [see comments]. Gastroenterology 1995;108:1470-8.
32. MANCHESTER {published data only} * Goddard CJR, Hunt L, Smith A, Fallowfield G, Rowan B, Warnes TW. A trial of ursodeoxycholic acid (UDCA) and colchicine in primary biliary cirrhosis (PBC) (AASLDabstract). Hepatology 1994;20:151A.
33. Goddard CJR, Smith A, Hunt L, Halder T, Hillier V, Rowan B, et al.Surrogate markers of response in a trial of ursodeoxycholic acid (UDCA) and colchicine in primary biliary cirrhosis (PBC).Gut 1995;36(Suppl 1):A30.
34. MAYO-I {published and unpublished data} Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson Er. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999;19(2):115-21.
35. Balan V, Dickson ER, Jorgensen R A, Lindor KD. Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis [see comments]. Mayo-Clin-Proc 1994;69:923-9.
36. Batts KP, Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Ludwig J, et al.The effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirhosis (AASLD Abstract). Hepatology 1993;18:175A.
37. Batts KP, Jorgensen RA, Dickson ER, Lindor KD. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis. American Journal of Gastroenterology 1996;91:2314-7.
38. Crippin JS, Jorgensen R, Dickson ER, Lindor KD. The effect of ursodeoxycholic acid compared to placebo on lumbar spine bone mineral density in patients with primary biliary cirrhosis. Gastroenterology 1991;100:A732.
39. Dickson ER, Lindor KD. Beneficial effects of ursodeoxycholic acid in an open trial of patients with primary biliary cirrhosis. Bile acids as therapeutic agents. From Basic Science to Clinical Practice. Falk Symposium 58. 1991:271-2.
40. Dickson ER, Lindor KD, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA.Ursodiol (URSO) is effective therapy for patients with primary biliary cirrhosis (PBC). Falk Symposium No. 68. XII International Bile Acid Meeting. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Basel. 1992:44.
41. Dickson ER, Lindor KD, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA. Ursodiol is effective therapy for patients with primary biliary cirrhosis. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Falk Symposium 68. 1993:292-3.
42. Jorgensen RA, Angulo P, Dickson ER, Lindor K. Results of long-term ursodiol treatment for patients with primary biliary cirrhosis. The American Journal of Gastroenterology 2002;97(10):2647-50.
43. Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Lindor KD. Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995;36:935-8.
44. Lacerda MA, Lindor KD, Jorgensen RA, Rossi SS, Hofmann AF, Salen GR, Dickson ER. Dissimilar patterns of serum and biliary bile acids in primary biliary cirrhosis (PBC) patients treated with ursodeoxycholic acid (UDCA). Hepatology 1993;18(4 (Part 2)):174 A.
45. Laurin JM, DeSotel CK, Jorgensen RA, Dickson ER, Lindor KD. The natural history of abdominal pain associated with primary biliary cirrhosis. American Journal of Gastroenterology 1994;89:1840-3.
46. Lindor KD, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Dickson ER. Ursodeoxycholic acid (UDCA) is beneficial therapy for patients with primary biliary cirrhosis (PBC) [AASLD abstract]. Hepatology 1992;16:91A.
47. * Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al.Ursodeoxycholic acid in the treatment of primary biliary cirrhosis [see comments]. Gastroenterology 1994;106:1284-90.
48. Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?. Hepatology 1995;21:389-92.
49. Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis.Mayo Clinic Proceedings.Mayo Clinic 1997;72:1137-40.
50. Lindor KD, Lacerda MA, Jorgensen RA, DeSotel CK, Batta AK, Salen G, et al.Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. American Journal of Gastroenterology 1998;93:1498-504.
51. Lindor KD, Therneau TM, Jorgensen RA, Malichoc M, Dickson ER. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996;110:1515-8.
52. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of ursodeoxycholic acid (UDCA) on survival in patients with primary biliary cirrhosis (PBC) [AASLD abstract]. Gastroenterology 1995;108(4): A1111.
53. Siegel JL, Jorgensen R, Angulo P, Lindor KD. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. Journal of Clinical Gastroenterology 2003;37(2):183-5.
54. Zukowski TH, Jorgensen RA, Dickson ER, Lindor KD. Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy. American Journal of Gastroenterology 1998;93:958-61.
55. MEXICO CITY {published data only} De la Mora G, Bobadilla J, Romero P, Rodríguez-Leal G, Morán S, Kershenobich D, et al.Does treatment with ursodeoxycholic acid (UDCA) really diminish cholesterol serum levels in primary biliary cirrhosis (PBC)? [IASL abstract]. Hepatology 1994;19:57I.
56. MILAN {published data only} * Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, et al.Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J-Hepatol 1993;17:332-8.
57. Italian Multicenter Project for UDCA Treatment in PBC. Ursodeoxycholic acid (UDCA) for symptomatic primary biliary cirrhosis (PBC): a double-blind multicenter trial (EASL abstract). J Hepatol 1989;9(Suppl 1):87.
58. Podda M, Almasio P, Battezzati PM, Crosignani A, and Italian Multicenter Group for the Study of UDCA in PBC. Long-term effect of the administration of ursodeocycholic acid alone or with colchicine in patients with primary biliary cirrhosis: a double-blind multicentre study. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Falk Symposium 68. 1993:310-5.
59. Podda M, Battezzati PM, Crosignani A, Bianchi FB, Fusconi M, Chiaramonte M, et al.Urodeoxycholic acid (UDCA) for symptomatic primary biliary cirrhosis (PBC): a double-blind multicenter trial [AASLD abstract]. Hepatology 1989;10:639.
60. NEWARK-II {published data only} Batta AK, Arora R, Salen G, O'Brian C, Senior JR. Effect of ursodiol on biliary bile acid composition and conjugation in patients with primary biliary cirrhosis. Gastroenterology 1990;98:222.
61. O'Brian CB, Senior JR, Sternlieb JM, Sample M, Saul SM, Arora R, et al.Ursodiol treatment of primary biliary cirrhosis. Gastroenterology 1990;98:A617.
62. O'Brian CB, Senior JR, Sternlieb JM, Saul SM. Caution: not all patients with primary biliary cirrhosis may successfully be treated by ursodiol. Second International Meeting on Pathochemistry, Pathophysiology and Pathomechanisms of the Biliary System and New Strategies for the Treatment of Hepato-Biliary Diseases. Bologna. 1990:208.
63. Senior JR, O'Brian CB, Dickson ER. Effect of oral ursodiol treatment on the predicted probability of mortality in primary biliary cirrhosis. Hepatology 1990;12:438.
64. * Senior JR, O'Brien CB.Mortality risk indices as outcome measures of the effectiveness of ursodeoxycholic acid treatment of cholestatic liver diseases. Bile Acids as Therapeutic Agents. From Basic Science to Clinical Practice. Falk Symposium 58. 1991:273-85.
65. NEWCASTLE {published and unpublished data} Myszor M, Turner I, Mitshison H, Bennett M, Burt AD, James OFW. No symptomatic or histological benefit from ursodeoxycholic acid treatment in PBC after 1 year.Controlled pilot study [IASL abstract]. Hepatology 1990;12:415.
66. * Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OF. A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 1994;9:162-8.
67. TAIPEI {published and unpublished data} * Hwang SJ, Chan CY, Lee SD, Wu JC, Tsay SH, Lo KJ. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. Journal of Gastroenterology and Hepatology 1993;8:217-23.
68. TOKYO {published data only} * Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, et al.A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirhosis. Gastroenterologia Japonica 1990;25:774-80.
69. Toda G, Oka H, Hasumura Y, Kamimura T, Ohat Y, Tsuji T, et al.A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis in Japan. XI International Bile Acid Meeting. Bile Acids as Therapeutic Agents - From Basic Science to Clinical Practice. Freiburg. 1990:76.
70. TORONTO {published data only} Ghent CN, Cauch-Dudek K, Heathcote EJ, and the Canadian PBC Trial Group. Ursodeoxycholic acid therapy effects on pruritus and fatigue in primary biliary cirrhosis. Hepatology 1997;26:438 A.
71. * Heathcote EJ, Cauch DK, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al.The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
72. Heathcote EJL, Cauch K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al.A double blind randomized controlled multi-centre trial of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC): results from a blinded interim analysis. XII International Bile Acid Meeting. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Basel. Falk Symposium No. 68. 1992:45.
73. Heathcote EJL, Cauch K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al.The Canadian multi-centre double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis [AASLD abstract]. Hepatology 1992;16:91A.
74. Heathcote EJL, Cauch K, Walker V, Blendis LM, Ghent CN, Pappas SC, et al.A four-year follow-up study of ursodeoxycholic acid therapy for primary biliary cirrhosis. Gastroenterology 1993;104:A914.
75. Heathcote EJL, Cauch K, Walker V, Blendis LM, Pappas SC, Wanless IR, et al.A double-blind randomized controlled multicentre trial of ursodeoxycholic acid in primary biliary cirrhosis: results from a 1991 interimanalysis. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Falk Symposium 68. 1993:294-8.
76. Kilmurry MR, Heathcote EJ, Cauch DK, O'Rourke K, Bailey RJ, Blendis LM, et al.Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?. Hepatology 1996;23:1148-53.
77. Neuman MG, Cameron RG, Shear NH, Blendis LM. Ursodeoxycholic acid reduces fibrosis in primary biliary cirrhosis (Abstract). XV International Bile Acid Meeting. Bile Acids and Cholestasis. Titisee, Germany. Falk Symposium No 108. 1998:59.
78. VILLEJUIF {published data only} Calmus Y, Poupon R. Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases. Biochimie 1991;73:1335-8.
79. Corpechot C, Carrat F, Bonnand A-M, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-9.
80. Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R. Histopathologic study of primary biliary cirrhosis and the effect of ursodeoyxhcolic acid treatment on histological progression. Hepatology 1999;29:1007-12.
81. Huet PM, Huet J, Hotte S. Long term effect of ursodeoxycholic acid (UDCA) on hepatic function and portal hypertension in primary biliary cirrhosis (PBC) [AASLD abstract]. Hepatology 1994;20:202A.
82. Huet PM, Willems B, Huet J, Poupon R. Effects of ursodeoxycholic acid (UDCA) on hepatic function and portal hypertension in primary biliary cirrhosis (PBC). XII International Bile Acid Meeting. Bile Acids and the Hepatobiliary System. From Basic Science to Clinical Practice. Basel. Falk Symposium No. 68. 1992:118.
83. Huet PM, Willems B, Huet J, Poupon R. Effects of ursodeoxycholic acid (UDCA) on hepatic function and portal hypertension in primary biliary cirrhosis (PBC) [AASLD abstract]. Hepatology 1990;12:907.
84. Poupon R, Poupon RE, the UDCA-PBC Group. Ursodeoxycholic acid for primary biliary cirrhosis. International Lugano Symposium on Biliary Physiology and Diseases: Strategies for the Treatment of Hepatobiliary Diseases. Lugano. Falk Symposium No. 53. 1989:22.
85. Poupon R, Poupon RE, The UDCA-PBC Group. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Strategies for the Treatment of Hepatobiliary Diseases. Falk Symposium 53. 1990:79-81.
86. Poupon R, the UDCA-PBC Group. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. First International Symposium. Trends and Discovery in Bile Acid Research. Bora-Bora (French Polynesia). 1990:123-6.
87. Poupon RE, Balkau B, Eschwege E, Poupon R, Kaplan MM. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. Annals of Internal Medicine 1991;115(6 Suppl 2):48.
88. * Poupon RE, Balkau B, Eschwege E, Poupon R, The UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. New England Journal of Medicine 1991;324:1548- 54.
89. Poupon RE, Balkau B, Guechot J, Heintzmann F. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 1994;19:635-40.
90. Poupon RE, Balkau B, Poupon R, The UDCA-PBC Group. Beneficial effect of ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC). Final results of the French Canadian trial [AASLD abstract]. Hepatology 1990;12:872.
91. Poupon RE, Chrétien Y, Balkau B, Niard AM, Poupon R, and the UDCA-PBC Study Group.Ursodeoxycholic therapy for primary biliary cirrhosis: a four year controlled study. Hepatology 1992;16:91A.
92. Poupon RE, Chretien Y, Poupon R, Paumgartner G. Serumbile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993;17:599-604.
93. Poupon RE, Eschwege E, Poupon R, Attali P, Capron JP, Erlinger S, et al.Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. Journal of Hepatology 1990;11(1):16-21.
94. Poupon RE, Ouguerram K, Chretien Y, Verneau C, Eschwege E, Magot T, et al.Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 1993;17:577-82.
95. Poupon RE, Poupon R, Balkau B, The UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group [see comments]. New England Journal of Medicine 1994;330:1342-7.
96. Poupon RE, Poupon R, UDCA-PBC Group. Ursodeoxycholic acid (UDCA) for treatment of primary biliary cirrhosis (PBC). Interim analysis of a double-blind multicenter randomized trial. Hepatology 1989;10:639.
97. Angulo 1999 {published data only} Angulo P, Batts K P, Therneau TM, Jorgensen R A, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999;29(3):644-7. [MEDLINE: 99162351]
98. Angulo 1999 a {published data only} Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, et al.Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30:830-5.
99. Bateson 1998 {published data only} Bateson MC, Gedling P. Ursodeoxycholic acid therapy for primary biliary cirrhosis. A 10-year British single-centre population-based audit of efficacy and survival. Postgraduate Medical Journal 1998;74(874):482-5.
100. Brodanova 1997 {published data only} Brodanova M, Perlik F. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis [Kyselina urzodeoxycholova v leceni primarni biliarny cirhozy]. Casopis Lekaru Ceskych 1997;136(7):215-20.
101. Cauch-Dudek 1998 {published data only} Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut 1998;43(5):705-10.
102. Crippa 1995 {published data only} Crippa G, Cagnoni C, Castelli A, Concesi C, Girometta S, Pancotti D, et al.Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis. Clinical Therapeutics 1995;146:367-72.
103. Crosignani 1996 {published data only} Crosignani A, Battezzati PM, Setchell KDR, Invernizzi P, Covini G, Zuin M, Podda M. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Digestive Diseases and Sciences 1996;41(4): 809-15.
104. Eisenburg 1988 {published data only} Eisenburg J, Eder M, Spengler U, Berg PA, Caselmann W, Mannes AG, Muntau A. Treatment of primary biliary cirrhosis with ursodeoxycholic acid. Part 2: Prospective long-term trial in 21 patients [Ursodesoxycholsaure bei Primar Biliarer Zirrhose. Teil 2: Prospektive Langzeitstudie an 21 Patienten]. Fortschritte der Medizin 1988;106(34):695-8.
105. Ferri 1993 {published data only} Ferri F, Bernocchi P, Fedeli S. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A controlled comparison with ursodeoxycholic acid [L'acido tauroursodesossicolico nel trattamento della cirrosi biliare primitiva. studio controllato in confronto ad acido ursodesossicolico]. Clinica Terapeutica 1993;143(4):321-6.
106. Grippa 1995 {published data only} Crippa G, Cagnoni C, Castelli A, Concesi C, Girometta S, Pancotti D, et al.Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis. Clinica Terapeutica 1995;146(5):367-72.
107. Ideo 1990 {published data only} Idéo G, Bellati G, Pedraglio E, Bottelli R, Maggi G. Efficacy of ursodeoxycholic acid in lowering alanine aminotransferase and gammaglutamyl transpeptidase serum levels in patients with chronic active hepatitis and primary biliary cirrhosis. Current Therapeutic Research Clinical and Experimental 1990;47(1):62-6.
108. Ikeda 1996 {published data only} Ikeda T, Tozuka S, Noguchi O, Kobayashi F, Sakamoto S, Marumo F, et al.Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: A prospective randomized study. Journal of Hepatology 1996;24(1):88-94.
109. Kehagioglou 1991 {published data only} Kehagioglou K, Dritsas S, Kanatakis S, Tsatsa E, Mastora M, Chrissikos N, Barbati K. Effect of UDCA on the natural course of PBC. Journal of Hepatology 1991;13(Suppl 2):S134.
110. Kim 1997 {published data only} Kim WR, Poterucha JJ, Jorgensen RA, Batts KP, Hombuger HA, Dickson-ER, et al.Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.Hepatology 1997;26(1):22-6.
111. Kneppelhout 1992 {published data only} Kneppelhout JC, Mulder CJJ, Van Berge Henegouwen GP, De Vries RA, Brandt K-H. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. Netherlands Journal of Medicine 1992;41(1):11-6.
112. Krzeski 1999 {published data only} Krzeski P, Habior A, Zych W, Walewska-Zielecka B, Butruk E. Effects of ursodeoycholic acid treatment on bilirubin concentration and survival of patients with primary biliary cirrhosis [Wplyw leczenia kwasem ursodezoksycholowym na stezenie bilirubiny i przezycie chorych z pierwotna zolciowa marskoscia watroby]. Gastroenterol Pol (Gastroenterologia-Polska) 1999;6(3):231-4.
113. Larghi 1997 {published data only} Larghi A, Crosignani A, Battezzati PM, De-Valle G, Allocca M, Invernizzi P, et al.Ursodeoxycholic and tauro-ursodeoxycholic acids for the treatment of primary biliary cirrhosis: A pilot crossover study. Alimentary Pharmacology and Therapeutics 1997;11(2):409-14.
114. Leuschner 1996 {published data only} Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. Journal of Hepatology 1996;25(1):49-57.
115. LONDON 1998 {published data only} Verma A, Ahmed HA, Jazrawi RP, Davis T, Bland M, Benson M, et al.Determining the most efficacious dose of ursodeoxycholic acid in primary biliary cirrhosis (Abstract). XV International Bile Acid Meeting. Bile Acids and Cholestasis. Falk Symposium No 108. Titisee, Germany. 1998:62.
116. Lotterer 1990 {published data only} Lotterer E, Stiehl A, Raedsch R, Foelsch UR, Bircher J. Ursodeoxycholic acid in primary biliary cirrhosis: No evidence for toxicity in the stages I to III. Journal of Hepatology 1990;10(3):284-90.
117. Matsuzaka 1994 {published data only} Matsuzaki Y, Doy M, Tanaka N, Shoda J, Osuga T, Nakano M, Aikawa T. Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis. Journal of Clinical Gastroenterology 1994;18(1):36-41.
118. Matsuzaki 1990 {published data only} Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, Nakano M. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. American Journal of Gastroenterology 1990;85(1):15-23.
119. MAYO-II 1997 {published data only} Lindor KD, Jorgensen R, Theneau TM, Smith C, Mahoney DW, Dickson ER. Comparison of three different doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. Hepatology 1997;26:438 A.
120. NEWARK-I {published data only} Batta AK, Arora R, Salen G, Katz S. Ursodeoxycholic acid improves liver function and reduces serum and urinary endogenous bile acids in primary biliary cirrhosis. Hepatology 1988;8:1221 (A).
121. Batta AK, Arora R, Salen G, Tint GS, Eskreis D, Katz S. Characterization of serumand urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. Journal of Lipid Research 1989;30:1953-62.
122. Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, et al.Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 1989;10:414-9.
123. Eskreis D, Abroon J, Katz S, Salen G, Arora R. Ursodeoxycholic acid treatment of primary biliary cirrhosis. American Journal of Gastroenterology 1988;83:1065 (A).
124. NEWARK-III {published data only} Batta AK, Salen G, Mirchandani R, Tint GS, Shefer S, Batta M, et al.Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am J Gastroenterol 1993;88:691-700.
125. Ogino 1993 {published data only} Ogino H, Unoura M, Kawai H, Terasaki S, Yanagi M, Matsushita E, et al.Effect of urosodeoxycholic acid therapy on lymphocyte function of patients with primary biliary cirrhosis. Acta Hepatologica Japonica 1993;34(4):306-12.
126. Okuyama 1988 {published data only} Okuyama S, Higuchi T, Ichimiya H, Hayashi H, Sakamoto N. A case of primary biliary cirrhosis - 4 years' treatment with 300 mg/day ursodeoxycholic acid. Acta Hepatologica Japonica 1988;29(6):799-802.
127. Osuga 1989 {published data only} Osuga T, Tanaka N, Matsuzaki Y, Aikawa T. Effect of ursodeoxycholic acid in chronic hepatitis and primary biliary cirrhosis. Digestive Diseases and Sciences 1989;34(12 SUPPL.):49S-51S.
128. Peridigoto 1992 {published data only} Perdigoto R, Wiesner RH. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology 1992;102(4):1389-91.
129. Podda 1989 {published data only} Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignan A, Petroni ML, Zuin M. Ursodeoxycholic acid for chronic liver diseases. Journal of Clinical Gastroenterology 1988;10((SUPPL. 2)):S25-S31.
130. Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Petroni ML, Zuin M. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Digestive Diseases and Sciences 1989;34(12 SUPPL.):59S-65S.
131. Poupon 1987 {published data only} Poupon R, Poupon RE, Calmus Y, et-al. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet 1987;1(8537):834-6.
132. Poupon 1989 {published data only} Poupon R, Balkau B, Legendre C, Lévy VG, Chrétien Y, Poupon RE. Ursodeoxycholic acid improves histologic features and progression of primary biliary cirrhosis. Hepatology 1989:637.
133. Poupon 1996 {published data only} Poupon RE, Huet PM, Poupon R, Bonnand A-M, Van Nhieu JT, Zafrani ES, et al.A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1996;24(5):1098-103.
134. Schonfeld 1997 {published data only} Schonfeld JV, Breuer N, Zotz RB, Beste M, Goebell H. Serial quantitative liver function tests in patients with primary biliary cirrhosis: A prospective long-term study. Digestion 1997;58(4):396-401.
135. Shibata 1992 {published data only} Shibata J, Fujiyama S, Honda Y, Sato T. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. Journal of Gastroenterology and Hepatology 1992;7(3):277-82.
136. Stiehl 1990 {published data only} Stiehl A, Rudolph G, Raedsch R, Moller B, Hopf U, Lotterer E, et al.Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990;12(3 I):492-7.
137. Taha 1994 {published data only} Taha AS, Allison MC, Myara A, Trivin F, Duncan A, Russell RI. Does cholestyramine reduce the efficacy of ursodeoxycholic acid in primary biliary cirrhosis?. European Journal of Gastroenterology and Hepatology 1994;6(6):535-8.
138. Takezaki 1991 {published data only} Takezaki E, Nishibayashi H, Murakami S, Kagawa K, Ohmori H, Kohda T, et al.A case of primary biliary cirrhosis with a histological improvement after long-term therapy with ursodeoxycholic acid. IRYO Japanese Journal of National Medical Services 1991;45(4):376-81.
139. Toda 1998 {published data only} Toda G, Tanaka N, Ikeda Y, Kobayashi K, Inoue K, Onji M, et al.Dose-dependency of effect of ursodeoxycholic acid on primary biliary cirrhosis: a randomised, double-blind controlled study. KAN-TAN-SUI (Japan) 1998;37:443-60.
140. Unoura 1990 {published data only} Unoura M, Ogino H, Mizuno Y, Urabe T, Matsushita E, Kaneko S, et al.Effects of ursodeoxycholic acid on lymphocyte functions in primary biliary cirrhosis. XI International Bile Acid Meeting. Bile Acids as Therapeutic Agents - From Basic Science to Clinical Practice. Freiburg. 1990:Abstract No. 77.
141. Van de Meeberg 1996 {published data only} van de Meeberg PC, Wolfhagen FH, Van Berge-Henegouwen GP, Salemans JM, Tangerman A, van Buuren HR, et al.Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. Journal of Hepatology 1996;25:887-94.
142. Van Hoogstraten 1998 {published data only} Van Hoogstraten HJ, De Smet MB, Renooij W, Breed JG, Engels LG, Den Ouden-Muller JW, et al.A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Aliment Pharmacol Ther 1998;12:965-71.
143. Verma 1999 {published data only} Verma A, Jazrawi RP, Ahmed HA, Davis T, Bland JM, Benson M, et al.Optimumdose of ursodeoxycholic acid in primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology 1999;11(10):1069-76.
144. Wirth 1994 {published data only} Wirth HP, Meyenberger C, Altorfer J, Ammann R, Blum HE. Eosinophilia in primary biliary cirrhosis: Regression under therapy with ursodeoxycholic acid [Eosinophilie bei Primar Biliarer Zirrhose: Regredienz unter Therapie mit Ursodesoxycholsaure]. Schweizerische Medizinische Wochenschrift 1994;124(19):810-5.
145. Wirth 1995 {published data only} Wirth HP, Zala G, Meyenberger Ch, Ammann R. Subtype pattern of antimitochondrial antibodies in primary biliary cirrhosis and response to ursodeoxycholic acid [Bedeutung des subtypen-musters antimitochondrialer Antikorper bei Primar Biliarer Zirrhose fur die Prognostischen Parameter und das Ansprechen auf Ursodesoxycholsaure]. Schweizerische Medizinische Wochenschrift 1995;125(15):750-4.
146. Wolfhagen 1994 {published data only} Wolfhagen FH, van Buuren HR, Schalm SW. Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis. The Netherlands Journal of Medicine 1994;44:84-90.
147. Yamazaki 1992 {published data only} Yamazaki M, Morimoto H, Wakabayashi T, Suzuki K, Kida H, Sugioka G, et al.A patient with asymptomatic primary biliary cirrhosis associated with eosinophilic infiltration and peripheral eosinophilia improved by the administration of ursodeoxycholic acid. Acta Hepatologica Japonica 1992;33(4):348-52.
148. Yamazaki 1996 {published data only} Yamazaki K, Nakadate I, Suzuki K, Sato S, Masuda T. Eosinophilia in primary biliary cirrhosis. American Journal of Gastroenterology 1996;91(3):516-22.
149. Yokomori 1996 {published data only} Yokomori H, Oda M, Kamegaya Y, Motoori T, Ohbu M, Ishii H. Rapid improvement of intractable pruritus in a case with primary biliary cirrhosis by a combined therapy of ursoderoxycholate (UDCA) and cholestyramine (CS) - Serumbile acid analysis. Acta Hepatologica Japonica 1996;37(2):102-8.
150. Ahrens 1950 Ahrens EH Jr, Payne MA, Kunkel HG, Eisenmenger WJ, Blondheim SH. Primary biliary cirrhosis (classical article). Medicine-Baltimore 1994;73(5):264-80.
151. Assmann 2000 Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9.
152. Baker 2003 Baker SG, Kramer BS. A perfect correlate dose not a surrogate make. BMC Medical Research Methodology 2003;3:16.
153. Begg 1994 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4): 1088-1101.
154. Calmus 1992 Calmus Y, Weill B, Ozier Y, Chereau C, Houssin D, Poupon R. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. Gastroenterogy 1992;103:617-21.
155. DeMets 1987 DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6:341-8.
156. DerSimonian 1986 DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
157. Egger 1997 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
158. Gamble 2005 Gamble C, Hollis S. Uncertainty method improved on best/worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 2005;58:579-88.
159. Gluud 2001 a Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis - lessons for the future. Journal of Hepatology 2001;34(5):787-8.
160. Gluud 2005 Gluud C, Als-Nielsen B, D'Amico G, Gluud LL, Khan S, Klingenberg SL, et al.Hepato-Biliary Group. About The Cochrane Collaboration (Collaborative Review Groups (CRGs)) 2005. Issue 3. Art. No.: LIVER.
161. Gluud 2007 Gluud C, Brok J, Gong Y, Koretz R. Hepatology may have problems with putative surrogate outcome measures. Journal of Hepatology 2007;46:734-42.
162. Goulis 1999 Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. The Lancet 1999;354:1053-60.
163. Higgins 2002 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21:1539-58.
164. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
165. ICH-GCP 1997 International Conference on Harmonisation of Technical Requiements for Registration of Pharmaceuticals for Human Use. Code of Federal Regulation & ICH Guidelines. Media: Parexel Barnett, 1997.
166. Ioannidis 2001 Ioannidis JPA, Lau J. Evolution of treatment effects over time: empirical insight from recursive cumulative metaanalyses. Proceedings of the National Academy of Sciences of the United States of America 2001;98(3):831-6.
167. Jazrawi 1994 Jazrawi RP, Caestecker JS, Goggin PM, Britten AJ, Joseph AEA, Maxwell JD, et al.Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.Gastroenterogy 1994;106:134-42.
168. Kaplan 1996 Kaplan MM. Primary biliary cirrhosis. New England Journal of Medicine 1996;335(21):1570-80.
169. Kaplan 2005 Kaplan MM, Gershwin ME. Primary biliary cirrhosis. New England Journal of Medicine 2005;353:1261-73.
170. Kim 2000 Kim WR, Lindor KD, Locke GR 3rd, Therneau TM, Homburger HA, Batts KP, et al.Epidemiology and natural history of primary biliary cirrhosis in a U.S. community. Gatroenterology 2000;119:1631-6.
171. Kjaergard 2001 Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11): 982-9.
172. Kürstein 2005 Kürstein P, Gluud L, Willemann M, Olsen K, Kjellberg J, Sogaard J, et al.Agreement between reported use of interventions for liver diseases and research evidence in Cochrane systematic reviews. Journal of Hepatology 2005;43:984-9.
173. MacMahon 1949 MacMahon HE, Thannhauser SJ. Xanthomatous biliary cirrhosis (a clinical syndrome). Annals of Internal Medicine 1949;30:121.
174. Mayo 2005 Mayo MJ. Patients and patience: the pitfalls of primary biliary cirrhosis trials. Nature Clinical Practise Gastroenterology & Hepatology 2005;2:552-3.
175. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
176. Oxman 1992 Oxman AD, Gayatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116:78-84.
177. Pares 2006 Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130(3):715-20.
178. Pasha 1997 Pasha TM, Dickson ER. Survival algorithms and outcome analysis in primary biliary cirrhosis. Seminars in Liver Disease 1997;17:147-58.
179. Pasha 1999 Pasha T, Heathcote J, Gabriel S, Cauch-Dudek K, Jorgensen R, Therneau T, et al.Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999;29:21-6.
180. Poupon 1997 Poupon RE, Lindor KD, Cauch-Dudek K, Dickson RE, Poupon R, Heathcote JE. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90.
181. Poupon 2000 Poupon RE. Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past - issues for the future. J Hepatol 2000;32:685-8.
182. Prince 2002 Prince M, Chetwynd A, Newman W, Metcalf JV, James OFW. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gatroenterology 2002;123:1044-51.
183. Prince 2003 Prince MI, James OFW. The epidemiology of primary biliary cirrhosis. Clinics in Liver Disease 2003;7:795-819.
184. Rust 2005 Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clinical Review in Allergy & Immunology 2005;28(2):135-45.
185. Schulz 1995 Schulz KF, Chalmers I, Hayes, R, Altman DG. Empirical evidence of bias. Dimensions of methdological quality associated with estimates of treatment in controlled trials. JAMA 1995;273:408-12.
186. Sharp 2000 Sharp SJ, Thompson SG. Analying the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. Statistics in Medicine 2000;19:3251-74.
187. Simko 1994 Simko V, Michael S, Prego V. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis. American Journal of Gastroenterology 1994;89:392-8.
188. Talwalker 2003 Talwalkar JA, Lindor KD. Primary biliary cirrhosis. The Lancet 2003;362:53-61.
189. Thompson 2002 Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Statistics in Medicine 2002;21(11):1559-73.
190. Whitehead 2002 Whitehead A. A Bayesian approach to meta-analysis. Meta-analysis of controlled clinical trials. Chichester, UK: John Wiley & Sons, Ltd, 2002:259-84.
191. Yusuf 1991 Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. JAMA 1991;266:93-8.
192. Christensen 1997 Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis (Protocol). The Cochrane Library 1997, Issue 4.
193. Gluud 1999 a Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis (Updated protocol). The Cochrane Library 1999, Issue 2.
194. Gluud 1999 b Gluud C, Christensen E. Ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC) - a Cochrane Hepato-Biliary systematic review. Journal of Hepatology 1999;30(Suppl 1):83 (Abstract).
195. Gluud 2001 b Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000551]